Karl-Johan Malmberg appointed "Scientist of the Month" by "Helse Sør-Øst" for February 2014

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".

For the month of February 2014, this honour went to Karl-Johan Malmberg from the Department of Immunology at the Institute of Cancer Research at the Divison of Cancer Medicine, Surgery and Transplantation at Oslo University Hospital.

Research is an area of commitment for the South-Eastern Norway Regional Health Authority, which spends a total of 1.4 thousand million NOK on research every year.

Links:

Popular scientific presentation of Malmberg's work, in Norwegian, by Knut Albert Solem, Oslo universitetssykehus - entitled "Mot neste generasjons celleterapi"

Helse Sør-Øst "Researcher of the month" archive

Karl-Johan Malmberg's publications

Home page of Karl-Johan Malmberg's research group: Natural Killer Cell Biology and Cell Therapy

Department of Immunology

Institute of Cancer Research

Previous news articles about Malmberg:

Karl-Johan Malmberg receives 12 million grant from Research Council

Karl-Johan Malmberg last author on publication in Blood on KIR expression patterns on CD8 T cells

Recent publications

From major journals, first or last author from the Institute for Cancer Research

Totland MZ, Knudsen LM, Rasmussen NL, Omori Y, Sørensen V, Elster VCW, Stenersen JM, Larsen M, Jensen CL, Zickfeldt Lade AA, Bruusgaard E, Basing S, Kryeziu K, Brech A, Aasen T, Lothe RA, Leithe E (2024)
The E3 ubiquitin ligase ITCH negatively regulates intercellular communication via gap junctions by targeting connexin43 for lysosomal degradation
Cell Mol Life Sci, 81 (1), 171
DOI 10.1007/s00018-024-05165-8, PubMed 38597989

Valsalakumari R, Pandya AD, Prasmickaite L, Kvalvaag A, Myrann AG, Åslund AKO, Kjos MS, Fontecha-Cuenca C, Haroon HB, Ribeiro ARS, Horejs-Hoeck J, Moghimi SM, Mørch Ý, Skotland T, Sandvig K, Mælandsmo GM, Iversen TG (2024)
Preclinical Efficacy of Cabazitaxel Loaded Poly(2-alkyl cyanoacrylate) Nanoparticle Variants
Int J Nanomedicine, 19, 3009-3029
DOI 10.2147/IJN.S450283, PubMed 38562610

Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
Radiother Oncol, 195, 110263 (in press)
DOI 10.1016/j.radonc.2024.110263, PubMed 38556173

More selected publications

Most recent publications

Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandaric L, Karjalainen-Lindsberg ML, Hyytiainen M, Varjosalo M, Myklebust JH, Leppa S (2024)
Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma
Blood Cancer Discov (in press)
DOI 10.1158/2643-3230.BCD-23-0182, PubMed 38630892

Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
Prostate (in press)
DOI 10.1002/pros.24711, PubMed 38629217

Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmerman MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C et al. (2024)
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
J Clin Invest, 134 (8)
DOI 10.1172/JCI168536, PubMed 38618957

More publications

Annual summary of publications